➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
McKinsey
Express Scripts
McKesson
Merck

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PERFOROMIST

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for PERFOROMIST

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00633776 Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT) Withdrawn Dey, L.P. Phase 4 2008-03-01 The purpose of this study is to compare the effects of nebulized formoterol fumarate (Perforomist) to dry-powder inhaler formoterol fumarate (Foradil). Perforomist is a solution that is made into very fine spray (using a nebulizer) that is then breathed in over 10-15 minutes. Foradil is taken in a single quick, deep inhalation.
NCT00633776 Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT) Withdrawn University of California, Los Angeles Phase 4 2008-03-01 The purpose of this study is to compare the effects of nebulized formoterol fumarate (Perforomist) to dry-powder inhaler formoterol fumarate (Foradil). Perforomist is a solution that is made into very fine spray (using a nebulizer) that is then breathed in over 10-15 minutes. Foradil is taken in a single quick, deep inhalation.
NCT01488019 Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate) Completed Dey Phase 4 2012-03-01 This study is a multi-center, randomized, placebo-controlled study to evaluate the long-term safety of Perforomist® inhalation therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD). Individual participation is approximately 54 weeks, including 52 weeks of double-blind treatment.
NCT02291016 COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers Recruiting Mylan Specialty L.P. N/A 2015-02-01 The purpose of this study is to compare drug delivery and lung function after treatment with formoterol from a nebulizer versus a dry powder inhaler (DPI) in patients recovering from severe exacerbations of COPD. This is to determine if one device is superior in providing better lung function and drug deposition in this clinical setting.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PERFOROMIST

Condition Name

Condition Name for PERFOROMIST
Intervention Trials
COPD 2
Chronic Obstructive Pulmonary Disease (COPD) 2
Emphysema 1
COPD Exacerbation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for PERFOROMIST
Intervention Trials
Pulmonary Disease, Chronic Obstructive 5
Lung Diseases, Obstructive 4
Lung Diseases 3
Emphysema 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for PERFOROMIST

Trials by Country

Trials by Country for PERFOROMIST
Location Trials
United States 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for PERFOROMIST
Location Trials
Oregon 2
South Carolina 2
Texas 1
North Carolina 1
Nevada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for PERFOROMIST

Clinical Trial Phase

Clinical Trial Phase for PERFOROMIST
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for PERFOROMIST
Clinical Trial Phase Trials
Completed 2
Recruiting 1
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for PERFOROMIST

Sponsor Name

Sponsor Name for PERFOROMIST
Sponsor Trials
Parexel 1
University of Tennessee Graduate School of Medicine 1
Mylan Specialty L.P. 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for PERFOROMIST
Sponsor Trials
Industry 5
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Mallinckrodt
Express Scripts
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.